Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

BACKGROUND: Patient selection for addition of anti-EGFR therapy to chemotherapy for patients with RAS and BRAF wildtype metastatic colorectal cancer can still be optimised. Here we investigate the effect of anti-EGFR therapy on survival in different consensus molecular subtypes (CMSs) and stratified...

Descripción completa

Detalles Bibliográficos
Autores principales: ten Hoorn, Sanne, Sommeijer, Dirkje W., Elliott, Faye, Fisher, David, de Back, Tim R., Trinh, Anne, Koens, Lianne, Maughan, Tim, Seligmann, Jenny, Seymour, Matthew T., Quirke, Phil, Adams, Richard, Richman, Susan D., Punt, Cornelis J. A., Vermeulen, Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505637/
https://www.ncbi.nlm.nih.gov/pubmed/34253874
http://dx.doi.org/10.1038/s41416-021-01477-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505637/
https://www.ncbi.nlm.nih.gov/pubmed/34253874
http://dx.doi.org/10.1038/s41416-021-01477-9

Ejemplares similares